<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seventy-nine consecutive children with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were treated with a uniform intensive radiotherapy-chemotherapy program including high-dose MTX and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> prophylaxis </plain></SENT>
<SENT sid="1" pm="."><plain>Burkitt-type NHL was diagnosed in 44% and convoluted cell-type NHL in 33% </plain></SENT>
<SENT sid="2" pm="."><plain>Complete remission rate was 97.5% </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-eight of 79 children (61%) remain progression-free after 18-78 months of follow-up </plain></SENT>
<SENT sid="4" pm="."><plain>Patients belonging to the Burkitt type subgroup showed a peculiar clinical behavior as well as a significantly shorter survival than the other NHL patients (3-year overall survival rates of 50% vs. 72%, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical stages were related to the progression-free survival </plain></SENT>
<SENT sid="6" pm="."><plain>It is concluded that treatment should be tailored according to the histology (Burkitt-type NHL vs. other histologic types) and the clinical stage </plain></SENT>
</text></document>